Search - tctmd.com

Displaying 61 - 80 of 275

Sort: Relevancy | Date

Presentation TCT 2017

Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials?

Presenter: James E. Udelson

November 01, 2017

Presentation TCT 2017

TAVR for Severe AS and Hypertrophic Cardiomyopathy

Presenter: Gregory P. Fontana, Amar Krishnaswamy

November 01, 2017

Presentation TCT 2017

Is Functional Capacity a Suitable Endpoint for Heart Failure Drug and Device Trials?

Presenter: Angeles Alonso Garcia

November 01, 2017

Presentation TCT 2017

Next Generation Bio Innovation

Presenter: Andreu M Climent, Amit N. Patel

October 31, 2017

Presentation TCT 2017

Heterogeneous Tissue Is Most Important! Reduction of the Substrate for Ventricular Arrhythmias Will Have Better Impact on Cardiovascular Mortality

Presenter: Andreu M Climent, Amit N. Patel, Angel Arenal

October 31, 2017

Presentation TCT 2017

Focal Reduction of Scar to Reduce Ventricular Arrhythmias

Presenter: Andreu M Climent, Amit N. Patel, Eugenio Cingolani

October 31, 2017

Presentation TCT 2017

The Clinical Point of View: The Need for and Challenges of Regenerative Strategies to Reduce Sudden Death

Presenter: Andreu M Climent, Amit N. Patel, Gary L. Schaer

October 31, 2017

Presentation TCT 2017

Case Presentation: Valve-in-Ring

Presenter: Mayra Guerrero, John G. Webb, Ganesh Manoharan

October 31, 2017

Presentation TCT 2017

Valve-in-Ring: Patient Selection, Technical Pearls, and Outcomes

Presenter: Mayra Guerrero, John G. Webb, Danny Dvir

October 31, 2017

Presentation TCT 2017

Case Presentation: Valve-in-Valve

Presenter: Mayra Guerrero, John G. Webb, Brian K. Whisenant

October 31, 2017

Presentation TCT 2017

Valve-in-Valve: Patient Selection, Technical Pearls, and Outcomes

Presenter: Mayra Guerrero, John G. Webb, Isaac George

October 31, 2017

Presentation TCT 2017

Case Presentation: Valve-in-MAC

Presenter: Mayra Guerrero, John G. Webb, Isaac George

October 31, 2017

$My Belief: Cell Therapy for Refractory Ischemia Is Ready for Daily Practice!$

Presentation TCT 2017

My Belief: Cell Therapy for Refractory Ischemia Is Ready for Daily Practice!

Presenter: Timothy D. Henry, Marc S. Penn

October 31, 2017

Presentation TCT 2017

Fenestrated EVAR: Current and Future Technology

Presenter: Brian G. DeRubertis, Peter A. Schneider, Virendra Patel

October 31, 2017

Presentation TCT 2017

What Can We Learn From CT Imaging to Guide ViMAC Procedures?

Presenter: Mayra Guerrero, John G. Webb, Philipp Blanke

October 31, 2017

Presentation TCT 2017

Acute and Long-term Outcomes of ViMAC: Improving Success Through Careful Patient Selection and Optimal Technique

Presenter: Mayra Guerrero, John G. Webb

October 31, 2017

Presentation TCT 2017

Critical Limb Ischemia Update, and the STOP-PAD Trial

Presenter: Timothy D. Henry, Marc S. Penn, Mehdi H. Shishehbor

October 31, 2017

Presentation TCT 2017

Surgical Perspectives on MAC and Bioprosthetic Valve and Ring Failures: Implications for Transcatheter Therapies

Presenter: Mayra Guerrero, John G. Webb, Patrick M. McCarthy

October 31, 2017

Presentation TCT 2017

New Strategies: Repetitive Injections

Presenter: Timothy D. Henry, Marc S. Penn, Ricardo Sanz-Ruiz

October 31, 2017

Presentation TCT 2017

New Trials: REGENT-VSEL

Presenter: Timothy D. Henry, Marc S. Penn, Wojtek Wojakowski

October 31, 2017

Advertisement

Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials?

TAVR for Severe AS and Hypertrophic Cardiomyopathy

Is Functional Capacity a Suitable Endpoint for Heart Failure Drug and Device Trials?

Next Generation Bio Innovation

Heterogeneous Tissue Is Most Important! Reduction of the Substrate for Ventricular Arrhythmias Will Have Better Impact on Cardiovascular Mortality

Focal Reduction of Scar to Reduce Ventricular Arrhythmias

The Clinical Point of View: The Need for and Challenges of Regenerative Strategies to Reduce Sudden Death

Case Presentation: Valve-in-Ring

Valve-in-Ring: Patient Selection, Technical Pearls, and Outcomes

Case Presentation: Valve-in-Valve

Valve-in-Valve: Patient Selection, Technical Pearls, and Outcomes

Case Presentation: Valve-in-MAC

My Belief: Cell Therapy for Refractory Ischemia Is Ready for Daily Practice!

Fenestrated EVAR: Current and Future Technology

What Can We Learn From CT Imaging to Guide ViMAC Procedures?

Acute and Long-term Outcomes of ViMAC: Improving Success Through Careful Patient Selection and Optimal Technique

Critical Limb Ischemia Update, and the STOP-PAD Trial

Surgical Perspectives on MAC and Bioprosthetic Valve and Ring Failures: Implications for Transcatheter Therapies

New Strategies: Repetitive Injections

New Trials: REGENT-VSEL

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content